Partner with Effectus to support a nearby clinical study for patients with squamous cell carcinoma of the anal canal (SCAC).
Provide your contact information in the “Sign Up Here” tab or below and a member of the Effectus team will reach out with program details. Should you have any questions prior, please call us directly at 973-753-2430.
About the Research Study
Incyte Corporation is currently conducting the POD1UM-303 Study, a phase 3 clinical study assessing the efficacy of carboplatin + weekly paclitaxel with retifanlimab (INCMGA00012) or carboplatin + weekly paclitaxel with placebo (randomized 1:1) in participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Retifanlimab is an anti-PD-1 antibody administered by IV every 4 weeks which has been administered to more than 600 patients. Participants assigned to placebo may be eligible at time of radiographic progressive disease to enter the Crossover period to receive open-label retifanlimab. This study will enroll an estimated 300 participants worldwide.
Study Resources
- Clinicaltrials.gov study information: Website
- POD1UM-202 trial data: Annual Meeting of European Society of Medical Oncology (ESMO), held virtually 19-21 September 2020 (Rao et al. Abstract #2006: POD1UM-202: Phase 2 Study of Retifanlimab in Patients With Squamous Carcinoma of the Anal Canal Who Progressed Following Platinum-Based Chemotherapy.)
- InterAACT trial data: Rao S, Sclafani F, Eng C, et al. International Rare Cancers Initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol 2020; 38:2510-2518.
- Incyte and clinical trials: Website
How You Can Get Involved
As a healthcare provider who manages adult SCAC patients, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the POD1UM-303 Study. You will be asked to utilize provided key study criteria to determine which of your patients may potentially be eligible, and consult with them in a neutral manner about the study to assess their interest in participating at a nearby study site. At the study site, patients will undergo formal study screening to determine eligibility.
Compensation at fair market value will be available for healthcare providers who participate and meet program requirements.
The Effectus Patient Identification and Consultation Program
Effectus Patient Identification and Consultation Program Overview
Support Provided
Effectus will be your trusted partner throughout your participation, helping to facilitate your patients to the study site and thus relieving the burden on your practice. If you wish to participate, you will be asked to review and sign a Services Agreement with Effectus, which outlines your program responsibilities and compensation. Participation is completely voluntary, and you can opt out at any time. Background on the study, program materials, and program logistics will be reviewed in detail during a 1-hour virtual training session, for which you will be compensated for time spent.
Why Participate?
By participating in the Effectus Patient Identification and Consultation Program supporting the POD1UM-303 Study, you will have the opportunity to contribute to the research and advancement of a potential SCAC treatment. The program also allows healthcare providers the opportunity to offer alternative potential new treatment options to their patients.
Sign a services
agreement.
Receive a package of
program materials and
complete a simple, one-hour
virtual training session.
Utilize key screening
criteria to identify
potentially eligible
patients.
If the patient meets the criteria,
conduct a neutral consultation
about the availability of the
nearby study and gauge the
patient’s interest.
If the patient is interested in
participation, our team of dedicated
Patient Facilitators help ensure a
smooth patient transfer from your
office to the study.
The patient is scheduled
and presents at the study
site for the screening
appointment.
The patient’s enrollment
status is determined and is
relayed back to the treating
HCP by Effectus.
For more information on our program, please visit https://www.effectusctr.com/physician-network/.
The Effectus Patient Identification and Consultation Program
Contact Us
Montana Markell, Project Coordinator
Phone: 973-753-2430
Email: mmarkell@effectusctr.com